Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
News Archive
News Archive Navigation
News Archive Navigation Language
October 2017
-
Media Release
Novartis: au troisième trimestre, croissance du chiffre d'affaires et du résultat dans toutes les divisions
Chiffre d'affaires net en hausse de 2% (tcc[1], +2% USD), avec une croissance dans toutes les divisions: Cosentyx (USD 556 millions, +83% tcc) a affiché une forte hausse dans toutes ses… -
Media Release
Novartis steigert im dritten Quartal Umsatz und Gewinn in allen Divisionen
Der Nettoumsatz steigt mit einem Wachstum in allen Divisionen um 2% (kWk[1], +2% USD): Cosentyx (USD 556 Millionen, +83% kWk) wächst in allen Indikationen stark Entresto (USD 128 Millionen, +… -
Media Release
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
Breakthrough Therapy Designation based on Phase III study showing the three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo1… -
Eye on patients, mind on innovation
New Global Head of Ophthalmology Research sees the eye as a frontier of biomedical research.
-
Bringing virtual reality to the lab
Novartis researchers want to use the technology to help them design new drugs.
-
Media Release
Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
Nearly 70% of patients maintained platelet counts of >=30×109/L without rescue therapy for prolonged periods, reducing the overall risk of bleeding More than one-third of patients permanently… -
Featured News
Novartis to host stakeholder dialogue on ways to improve access to healthcare in lower-income countries
The event will take place on November 21 in Basel.
-
A fitness trainer strives to keep his mother’s mind limber
On Friday nights, Juan Pedro García Hernández goes dancing – but for rest of the time he’s taking care of his mother.
-
Featured News
CAR-T therapies are manufactured for each individual patient
Individualized CAR‑T therapy uses a patient’s own immune system to fight certain types of cancers.
-
Researcher’s Ph.D. leads to medical breakthrough in rare skin disease
A researcher in South Africa investigating a rare skin disease was losing hope of a breakthrough. Then she made a discovery.
-
A groundskeeper tackles cancer in several ways
In Australia, a country where skin cancer rates remain high, cancer survivor Malcolm Caddies is on a mission to prevent the risks of sun exposure.
-
Researcher races to find new treatment for his progressive disease
Ice hockey used to help Tyler Patron combat cystic fibrosis, but he hopes the lab could yield stronger medicine.
Pagination
- ‹ Previous page
- 1
- …
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- …
- 154
- › Next page
Test disclaimer...!!!